II/III期结直肠癌术后血清CEA变化与预后的相关性研究
A Study on the Correlation between Postoperative Changes in Serum Carcinoembryonic Antigen (CEA) Levels and Prognosis in Patients with Stage II/III Colorectal Cancer after Surgery
摘要: 结直肠癌(CRC)是全球高发的恶性肿瘤之一，术后复发是影响患者预后的重要因素。癌胚抗原(CEA)作为CRC临床管理中应用最广泛的肿瘤标志物，其术后动态变化与肿瘤复发密切相关。本文通过综述现有研究，系统探讨II/III期结直肠癌患者术后血清CEA水平的变化模式及其对肿瘤复发的预测价值，分析其在临床应用中的实际价值，并展望未来研究方向，以期为优化术后监测策略提供理论依据。
Abstract: Colorectal cancer (CRC) is one of the most frequently occurring malignant tumors worldwide, and postoperative recurrence is a significant factor affecting patient prognosis. Carcinoembryonic antigen (CEA), as the most widely used tumor marker in the clinical management of CRC, is closely related to tumor recurrence through its dynamic changes postoperatively. This paper systematically reviews existing studies to explore the change patterns of postoperative serum CEA levels in patients with stage II/III colorectal cancer and their predictive value for tumor recurrence. It analyzes the practical value of CEA in clinical applications and prospects future research directions, aiming to provide a theoretical basis for optimizing postoperative monitoring strategies.
文章引用：乔建伟, 李伟杰, 高池, 邰智慧. II/III期结直肠癌术后血清CEA变化与预后的相关性研究[J]. 医学诊断, 2025, 15(3): 290-296. https://doi.org/10.12677/md.2025.153038

参考文献

[1] 中华医学会肿瘤学分会, 国家卫生健康委员会医政司. 中国结直肠癌诊疗规范(2023版) [J]. 协和医学杂志, 2023, 14(4): 706-733.
[2] Van Cutsem, E., Cervantes, A., Nordlinger, B. and Arnold, D. (2014) Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, III1-III9. [Google Scholar] [CrossRef] [PubMed]
[3] Porschen, R., Bermann, A., Löffler, T., Haack, G., Rettig, K., Anger, Y., et al. (2001) Fluorouracil Plus Leucovorin as Effective Adjuvant Chemotherapy in Curatively Resected Stage III Colon Cancer: Results of the Trial AdjCCA-01. Journal of Clinical Oncology, 19, 1787-1794. [Google Scholar] [CrossRef] [PubMed]
[4] Steele, S.R., Chang, G.J., Hendren, S., Weiser, M., Irani, J., Buie, W.D., et al. (2015) Practice Guideline for the Surveillance of Patients after Curative Treatment of Colon and Rectal Cancer. Diseases of the Colon & Rectum, 58, 713-725. [Google Scholar] [CrossRef] [PubMed]
[5] Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., et al. (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2019 for the Treatment of Colorectal Cancer. International Journal of Clinical Oncology, 25, 1-42. [Google Scholar] [CrossRef] [PubMed]
[6] Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., et al. (2020) Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 31, 1291-1305. [Google Scholar] [CrossRef] [PubMed]
[7] Pu, H., Xie, P., Chen, Y., Zhao, Y., Ye, X., Lu, G., et al. (2021) Relationship between Preoperative and Postoperative Serum Carcinoembryonic Antigen and Prognosis of Patients with Stage I-III Rectal Cancer: A Retrospective Study of a Multicentre Cohort of 1022 Rectal Cancer Patients. Cancer Management and Research, 13, 2643-2651. [Google Scholar] [CrossRef] [PubMed]
[8] Li, C., Zhang, D., Pang, X., Pu, H., Lei, M., Fan, B., et al. (2021) Trajectories of Perioperative Serum Tumor Markers and Colorectal Cancer Outcomes: A Retrospective, Multicenter Longitudinal Cohort Study. eBioMedicine, 74, Article 103706. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, H.R., Joo, J.I., Lim, S.W. and Oh, B.Y. (2021) Prognostic Value of Carcinoembryonic Antigen Levels before and after Curative Surgery in Colon Cancer Patients. Annals of Surgical Treatment and Research, 100, 33-39. [Google Scholar] [CrossRef] [PubMed]
[10] Islam, M.R., Akash, S., Rahman, M.M., Nowrin, F.T., Akter, T., Shohag, S., et al. (2022) Colon Cancer and Colorectal Cancer: Prevention and Treatment by Potential Natural Products. Chemico-Biological Interactions, 368, Article 110170. [Google Scholar] [CrossRef] [PubMed]
[11] Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. [Google Scholar] [CrossRef] [PubMed]
[12] Brenner, H. and Chen, C. (2018) The Colorectal Cancer Epidemic: Challenges and Opportunities for Primary, Secondary and Tertiary Prevention. British Journal of Cancer, 119, 785-792. [Google Scholar] [CrossRef] [PubMed]
[13] 王锡山. 从中美结直肠癌流行病学特征看结直肠癌早诊早治的重要性[J]. 中华结直肠疾病电子杂志, 2021, 10(1): 26-33.
[14] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[15] Cao, W., Chen, H., Yu, Y., Li, N. and Chen, W. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef] [PubMed]
[16] 黄理宾, 黄秋实, 杨烈. 全球及中国的结直肠癌流行病学特征及防治: 2022《全球癌症统计报告》解读[J]. 中国普外基础与临床杂志, 2024, 31(5): 530-537.
[17] Wang, Q., Zhou, Y., Zhou Ge, Y., Qin, G., Yin, T., Zhao, D., et al. (2022) Comprehensive Proteomic Signature and Identification of CDKN2A as a Promising Prognostic Biomarker and Therapeutic Target of Colorectal Cancer. World Journal of Clinical Cases, 10, 7686-7697. [Google Scholar] [CrossRef] [PubMed]
[18] Valle, L., de Voer, R.M., Goldberg, Y., Sjursen, W., Försti, A., Ruiz-Ponte, C., et al. (2019) Update on Genetic Predisposition to Colorectal Cancer and Polyposis. Molecular Aspects of Medicine, 69, 10-26. [Google Scholar] [CrossRef] [PubMed]
[19] Rawla, P., Sunkara, T. and Barsouk, A. (2019) Epidemiology of Colorectal Cancer: Incidence, Mortality, Survival, and Risk Factors. Gastroenterology Review, 14, 89-103. [Google Scholar] [CrossRef] [PubMed]
[20] Zhao, H., Ming, T., Tang, S., Ren, S., Yang, H., Liu, M., et al. (2022) Wnt Signaling in Colorectal Cancer: Pathogenic Role and Therapeutic Target. Molecular Cancer, 21, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
[21] La Vecchia, S. and Sebastián, C. (2020) Metabolic Pathways Regulating Colorectal Cancer Initiation and Progression. Seminars in Cell & Developmental Biology, 98, 63-70. [Google Scholar] [CrossRef] [PubMed]
[22] Pabla, B. (2015) Colon Cancer and the Epidermal Growth Factor Receptor: Current Treatment Paradigms, the Importance of Diet, and the Role of Chemoprevention. World Journal of Clinical Oncology, 6, 133-141. [Google Scholar] [CrossRef] [PubMed]
[23] Di, Y., Jing, X., Hu, K., Wen, X., Ye, L., Zhang, X., et al. (2023) The C-MYC-WDR43 Signalling Axis Promotes Chemoresistance and Tumour Growth in Colorectal Cancer by Inhibiting P53 Activity. Drug Resistance Updates, 66, Article 100909. [Google Scholar] [CrossRef] [PubMed]
[24] Du, M., Chen, W., Zhang, W., Tian, X., Wang, T., Wu, J., et al. (2018) TGF-β Regulates the ERK/MAPK Pathway Independent of the SMAD Pathway by Repressing Mirna-124 to Increase MALAT1 Expression in Nasopharyngeal Carcinoma. Biomedicine & Pharmacotherapy, 99, 688-696. [Google Scholar] [CrossRef] [PubMed]
[25] David, C.J. and Massagué, J. (2018) Contextual Determinants of TGFβ Action in Development, Immunity and Cancer. Nature Reviews Molecular Cell Biology, 19, 419-435. [Google Scholar] [CrossRef] [PubMed]
[26] Peng, D., Fu, M., Wang, M., Wei, Y. and Wei, X. (2022) Targeting TGF-β Signal Transduction for Fibrosis and Cancer Therapy. Molecular Cancer, 21, Article No. 104. [Google Scholar] [CrossRef] [PubMed]
[27] 刘锦燕, 郑彧鸣, 曹祎婕, 等. 结直肠癌诊断性生物标志物的研究进展[J]. 标记免疫分析与临床, 2022, 29(9): 1592-1596.
[28] Hur, K., Toiyama, Y., Okugawa, Y., Ide, S., Imaoka, H., Boland, C.R., et al. (2015) Circulating MicroRNA-203 Predicts Prognosis and Metastasis in Human Colorectal Cancer. Gut, 66, 654-665. [Google Scholar] [CrossRef] [PubMed]
[29] Jin, X., Lu, S. and Wang, A. (2020) Expression and Clinical Significance of mIR-4516 and mIR-21-5p in Serum of Patients with Colorectal Cancer. BMC Cancer, 20, Article No. 241. [Google Scholar] [CrossRef] [PubMed]
[30] Sonoda, H., Yamada, T., Matsuda, A., Ohta, R., Shinji, S., Yokoyama, Y., et al. (2021) Elevated Serum Carcinoembryonic Antigen Level after Curative Surgery Is a Prognostic Biomarker of Stage II-III Colorectal Cancer. European Journal of Surgical Oncology, 47, 2880-2887. [Google Scholar] [CrossRef] [PubMed]
[31] Tie, J., Cohen, J.D., Wang, Y., Christie, M., Simons, K., Lee, M., et al. (2019) Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 5, 1710-1717. [Google Scholar] [CrossRef] [PubMed]
[32] Reinert, T., Henriksen, T.V., Christensen, E., Sharma, S., Salari, R., Sethi, H., et al. (2019) Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients with Stages I to III Colorectal Cancer. JAMA Oncology, 5, 1124-1131. [Google Scholar] [CrossRef] [PubMed]
[33] Ko, K., Kananazawa, Y., Yamada, T., Kakinuma, D., Matsuno, K., Ando, F., et al. (2021) Methylation Status and Long‐fragment Cell‐Free DNA Are Prognostic Biomarkers for Gastric Cancer. Cancer Medicine, 10, 2003-2012. [Google Scholar] [CrossRef] [PubMed]
[34] Iwai, T., Yamada, T., Takahashi, G., Takeda, K., Koizumi, M., Shinji, S., et al. (2020) Circulating Cell-Free Long DNA Fragments Predict Post-Hepatectomy Recurrence of Colorectal Liver Metastases. European Journal of Surgical Oncology, 46, 108-114. [Google Scholar] [CrossRef] [PubMed]
[35] Diehl, F., Schmidt, K., Choti, M.A., Romans, K., Goodman, S., Li, M., et al. (2008) Circulating Mutant DNA to Assess Tumor Dynamics. Nature Medicine, 14, 985-990. [Google Scholar] [CrossRef] [PubMed]
[36] Diehl, F., Schmidt, K., Durkee, K.H., Moore, K.J., Goodman, S.N., Shuber, A.P., et al. (2008) Analysis of Mutations in DNA Isolated from Plasma and Stool of Colorectal Cancer Patients. Gastroenterology, 135, 489-498.E7. [Google Scholar] [CrossRef] [PubMed]
[37] Bedin, C., Enzo, M.V., Del Bianco, P., Pucciarelli, S., Nitti, D. and Agostini, M. (2017) Diagnostic and Prognostic Role of Cell‐Free DNA Testing for Colorectal Cancer Patients. International Journal of Cancer, 140, 1888-1898. [Google Scholar] [CrossRef] [PubMed]
[38] Konishi, T., Shimada, Y., Hsu, M., Tufts, L., Jimenez-Rodriguez, R., Cercek, A., et al. (2018) Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome. JAMA Oncology, 4, 309-315. [Google Scholar] [CrossRef] [PubMed]
[39] Engstrom, P.F., Arnoletti, J.P., Benson, A.B., et al. (2009) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 7, 778-831.
[40] Ito, K. (2002) Usefulness of Analytical CEA Doubling Time and Half-Life Time for Overlooked Synchronous Metastases in Colorectal Carcinoma. Japanese Journal of Clinical Oncology, 32, 54-58. [Google Scholar] [CrossRef] [PubMed]
[41] 张小丽, 马玉芳, 肖骁, 等. 直肠癌患者术后术前CEA差值与临床预后的相关性研究[J]. 世界最新医学信息文摘, 2019, 19(28): 274-275.
[42] Shinkins, B., Primrose, J.N., Pugh, S.A., Nicholson, B.D., Perera, R., James, T., et al. (2019) Serum Carcinoembryonic Antigen Trends for Diagnosing Colorectal Cancer Recurrence in the FACS Randomized Clinical Trial. British Journal of Surgery, 106, 728-728. [Google Scholar] [CrossRef] [PubMed]
[43] Shen, D., Wang, X., Wang, H., Xu, G., Xie, Y., Zhuang, Z., et al. (2022) Current Surveillance after Treatment Is Not Sufficient for Patients with Rectal Cancer with Negative Baseline CEA. Journal of the National Comprehensive Cancer Network, 20, 653-662.e3. [Google Scholar] [CrossRef] [PubMed]
[44] 李鹏昊, 郝敬鹏, 史刚刚, 等. 胸苷激酶1、癌胚抗原和糖类抗原在结直肠肿瘤中的表达及临床意义[J]. 国际生物医学工程杂志, 2020, 43(4): 287-291.